Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Chemical Works of Gedeon Richter Days Payable?
Chemical Works of Gedeon RichterRGEDF +3.37%97 Days Payable is 51.69 as of Jun. 2026, which is 43% below its 10-year median of 90.71. GuruFocus rates RGEDF with a GF Score™ of 97/100 and a GF Value™ of $36.36 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 925 Drug Manufacturers companies, Chemical Works of Gedeon Richter ranks better than 73.41% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter Days Payable Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemical Works of Gedeon Richter Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's Days Payable distribution charts can be found below:
* The bar in red indicates where Chemical Works of Gedeon Richter's Days Payable falls into.
Chemical Works of Gedeon Richter Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter (RGEDF) has a Days Payable of 51.69 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chemical Works of Gedeon Richter and its competitors. This is 43% below median its historical median of 90.71. Over the past decade, Chemical Works of Gedeon Richter's Days Payable has ranged from 62.62 to 118.06. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #246 out of 925 companies in the Drug Manufacturers industry, placing it in the top 26.6%.
Is Chemical Works of Gedeon Richter's Days Payable too high?
Chemical Works of Gedeon Richter's current Days Payable of 51.69 is 43% below median its 10-year median of 90.71. Over the past 10 years, this metric has ranged from a low of 62.62 to a high of 118.06. The Drug Manufacturers industry median Days Payable is 89.79. Chemical Works of Gedeon Richter's value of 51.69 is 42.4% below this industry median. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #246 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 97/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #246 out of 925 companies for Days Payable. This puts Chemical Works of Gedeon Richter in the upper half of its industry. The industry median Days Payable is 89.79. Chemical Works of Gedeon Richter's value of 51.69 is 42.4% below this benchmark. Historically, Chemical Works of Gedeon Richter's own Days Payable has ranged from 62.62 to 118.06 over the past decade. While the company's 10-year median is 90.71 vs. the industry median of 89.79, Chemical Works of Gedeon Richter has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.79, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemical Works of Gedeon Richter's current Days Payable of 51.69 is 42.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chemical Works of Gedeon Richter and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current Days Payable is 51.69, which is 43% below median its own 10-year median of 90.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $36.36, compared to a current price of $41.48 — trading 14.1% above its estimated fair value. The current Days Payable is 51.69, which is 43% below median its 10-year median of 90.71 and 42.4% below the Drug Manufacturers industry median of 89.79. Chemical Works of Gedeon Richter's overall GF Score™ is 97/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current Days Payable is 51.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued.
The current stock price of $41.48 is trading 14.1% above its estimated GF Value™ of $36.36.
GuruFocus considers Chemical Works of Gedeon Richter to be Modestly Overvalued.
Key valuation signals for RGEDF:
Days Payable: 51.69 (43% below median its 10-year median of 90.71)
GF Value™: $36.36 vs. price of $41.48 (14.1% above fair value)
Industry Position: 42.4% below the Drug Manufacturers median (#246 of 925)
No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
97GF Score
Get the complete analysis for RGEDF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEDF has been successfully added to your 
